Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, shared on X:
“Title: Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison
Authors: Naveen Pemmaraju, Alessandro Lucchesi, Stephen T. Oh, Koo Wilson, Zalmai Hakimi, Sarah A. Buckley, Purvi Suthar, Mikolaj Parkitny, Piotr Wojciechowski, Klaudia Kolonko, John O. Mascarenhas
Title: TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Authors: Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, Francesca Palandri, Steffen Koschmieder, Robert Delage, Jean-Jacques Kiladjian, Christopher B. Benton, Srinivas K. Tantravahi, Noa Lavi, Su-Peng Yeh, Maria Teresa Gomez Casares, Emanuele Ammatuna, Andrew Bruce McDonald, Sung-Soo Yoon, Keita Kirito, Timothy Devos, Andrew C. Perkins, Atanas Radinoff, Omur Gokmen Sevindik, Andrija Bogdanovic, Rastislav Moskal, Jason G. Harb, Bryan C. Murray, Qi Jiang, Avijeet S. Chopra, Elektra J. Papadopoulos, Jalaja Potluri, Francesco Passamonti
Other articles about hematology on OncoDaily.